Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors

Trial Details

NCT ID
NCT06666270
Phase
PHASE1
Sponsor
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • SYN818
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Having signed the written Informed Consent Form (ICF);
  • Male or female aged ≥18 years;
  • Life expectancy ≥12 weeks;
  • Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →